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Osteopontin might be involved in bone remodelling rather than in
inflammation in ankylosing spondylitis
S. T. Choi1, J. H. Kim1, E.-J. Kang1, S.-W. Lee1, M.-C. Park1, Y.-B. Park1 and S.-K. Lee1
Objectives. To determine whether osteopontin (OPN) is increased in patients with AS and to investigate its relationship to inflammatory
disease activity and bone remodelling process.
Methods. This cross-sectional study included 30 patients with AS and 23 age- and sex-matched healthy controls. We assessed clinical
characteristics and laboratory parameters including the ESR, CRP, lipid profiles, the Bath AS disease activity index (BASDAI) and the Bath
AS radiographic index (BASRI). To evaluate bone metabolism, we tested ALP, OCN and C-telopeptide of type I collagen (CTX-I). Plasma
levels of OPN, TNF- and IL-6 were measured by ELISA, and mRNA expression in peripheral blood mononuclear cells (PBMCs) was
performed by RT–PCR. Changes in OPN level were also evaluated in eight patients after the treatment with a TNF- blocker.
Results. Patients with AS had significantly higher plasma OPN, TNF- and IL-6 levels and more mRNA expression than healthy controls.
Plasma OPN levels were correlated with serum ALP, OCN and CTX-I levels, but not with ESR, CRP, lipid profiles, BASDAI or BASRI.
Treatment with a TNF- blocker did not alter OPN levels, although it reduced the disease activity.
Conclusions. Patients with AS had higher levels of OPN compared with controls. The plasma OPN level was correlated with serum ALP,
OCN and CTX-I levels, but not with disease activity in AS. OPN might be involved in bone remodelling rather than in inflammation in AS.
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Introduction
The inflammatory process of AS usually involves the sacroiliac
joints, and the vertebral column is typically affected as the disease
progresses. The production of several pro-inflammatory cyto-
kines, such as TNF- and IL-6, is increased in patients with AS
[1–3]. The findings that TNF- is overexpressed in sacroiliac joints
and IL-6 levels are correlated with ESR and CRP in the patients
with AS suggest that these cytokines are associated with the
process of inflammation [1–4]. In addition to spinal inflammation,
a characteristic feature of AS is new bone growth that leads to
syndesmophyte formation and ankylosis of the vertebrae [5].
Moreover, it has been reported that the majority of patients with
AS had reduced bone density, and patients with syndesmophytes
have greatly reduced bone density than do those without [6].
This suggests that bone growth and bone loss occur in parallel
in AS patients. However, the pathogenesis of this process remains
obscure.
Osteopontin (OPN) is a secreted phosphoglycoprotein weigh-
ing 34 kDa that was identified from the bone’s extracellular
matrix [7]. OPN is expressed by various cell types, including
osteoclasts, osteoblasts, chondrocytes, macrophages, activated T
cells, smooth muscle cells and epithelial cells, and is present in
several tissues including bone, kidney, placenta, smooth muscle
and secretary epithelia [8–10]. There is evidence suggesting that
OPN acts as a pro-inflammatory cytokine and plays an important
role in regulating inflammation [11]. It can be induced by
inflammatory mediators such as IL-1, TNF- and platelet-derived
growth factor [8]. At sites of inflammation, it promotes macro-
phage infiltration and dendritic cell migration to lymph nodes
[12, 13]. OPN is concerned in human atherosclerosis formation,
especially in advanced atherosclerotic plaque, may act as positive
regulators of vascular calcification [14, 15]. OPN is also involved
in the bone remodelling process [16–19]. Bone cells secrete OPN
physiologically during the process of bone remodelling. Osteo-
clasts may be the source of OPN in the cement lines of bone
during remodelling [16, 19]. The function of OPN in osteoclasts
may be to promote cell adhesion and chemotaxis during bone
resorption [16, 20]. In addition, OPN exists in situ in osteoblasts
and accumulates in mineralized bone matrix during endochon-
dral and intramembranous ossification [16, 18]. OPN enhances
osteoblastic differentiation and proliferation, and increases ALP
activity [21–23]. OPN is thought to be a candidate molecule for
the bone remodelling process in AS, in that it can induce both
bone formation and resorption.
In the murine CIA model, it has been reported that plasma
OPN levels and expression of OPN mRNA in peripheral blood
mononuclear cells (PBMCs) are markedly elevated at points
corresponding to arthritis flares [24, 25]. Moreover, the use of
specific antibodies reacting to OPN could inhibit inflammatory
cell infiltration and bony erosion in arthritic joints [25]. Over-
expression of plasma OPN protein and OPN mRNA in PBMC
have also been reported in human RA [26, 27].
These observations led us to hypothesize that OPN may be
involved in the pathogenesis of AS through inflammation and/or
the bone remodelling process. Therefore, we examined whether
OPN was increased in patients with AS and assessed the
association between OPN expression and disease activity para-
meters, bone remodelling markers and the expression of pro-
inflammatory cytokines such as TNF- and IL-6. We found that
OPN might be involved in bone remodelling rather than in
inflammation in AS patients.
Methods
Study design and patient population
This cross-sectional study included 30 patients with AS and
23 healthy controls. Consecutive patients with AS were selected
from an outpatient rheumatology clinic at Severance Hospital,
Seoul, Korea. The study was approved by the institutional ethics
committee and we obtained informed patient consent from all of
the patients and healthy volunteers. Patients diagnosed with AS
according to the 1966 New York criteria were included in the
study. All patients were selected independently of disease activity
status. Exclusion criteria were systemic diseases such as diabetes
mellitus, congestive heart failure, pregnancy, infectious process,
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impaired renal function (creatinine clearance <60ml/min),
elevated hepatic enzyme levels (twice the upper limit of normal
level) and history of anti-TNF- treatment (infliximab, etanercept
or adalimumab) prior to this study. Controls were healthy
individuals matched for age and sex. We followed OPN expression
in eight patients who were treated with a TNF- blocker after
enrolment in this study to compare OPN levels before and after
anti-TNF- treatment.
Clinical and laboratory assessment
Age, sex, medication history, BMI, duration of disease and extra-
articular manifestations of AS were recorded. Complete blood
count and routine biochemical analysis, including lipid profiles
and HLA-B27, were studied. We evaluated the following disease
activity markers: ESR, CRP and Bath AS disease activity index
(BASDAI). Bath AS radiology index (BASRI) was evaluated for
grading radiographic changes. ALP and OCN were measured
to assess bone formation, and serum C-telopeptide of type I
collagen (CTX-I) was measured to assess bone resorption (ALP;
Eiken Chemical Co., Tokyo, Japan; OCN, CTX-I; Roche Inc.,
Mannheim, Germany). OCN and CTX-I were measured by
electrochemiluminescence immunoassays (ECLIAs) according to
the manufacturer’s recommendations. The intra- and interassay
coefficients of variation (CVs) of OCN were 1.4–4.0% and
1.8–6.5%, respectively. Intra- and interassay CVs were 1.0–4.6%
and 1.6–4.7% for CTX-I, respectively.
Plasma protein and cytokine analysis
Plasma concentrations of OPN, TNF- and IL-6 were measured
by sandwich ELISAs (R&D Systems Inc., Minneapolis, MN,
USA) according to the manufacturer’s recommendations. The
intra- and interassay CVs of OPN were 2.9–4.0% and 5.4–6.6%,
respectively. Intra- and interassay CVs were 4.6–5.2% and
5.4–7.4% for TNF-, and 3.0–5.8 and 6.3–9.6% for IL-6. All
assays represented duplicate measurements. A standard curve was
drawn by plotting OD vs the log of recombinant OPN, TNF-
and IL-6 concentrations, and the coefficient of determination (R2)
of these were 0.9970, 0.9943 and 0.9993, respectively.
RNA extraction and RT–PCR analysis of gene expression
of OPN and cytokines
Expressions of OPN and cytokine mRNA were measured by
RT–PCR using specific primers and probes in all AS patients and
healthy controls (OPN: forward 50-GGAACAAGGATAGG
TAGGCT-30, reverse 30-AGTTTAGCTTTGTGATTTCG-50;
TNF-: forward 50-GTGGAGATCTCTTCTTGCAC-30, reverse
30-AGTGCCCTTAACATTCTAA-50; IL-6: forward 50-ACTCA
CCTCTTCAGAACGAA-30, Reverse 30-GTCTCCTCATTGAA
TCCAGA-50). PBMCs were obtained by Ficoll-Hypaque density
gradient centrifugation. Total RNA was extracted from PBMCs
using TRIzol reagent (Life Technologies, Mississauga, ON,
Canada). One microgram of RNA was combined with superscript
II (Invitrogen, Burlington, ON, Canada) in a 20-l reaction
volume for 30min at 428C and then heated to 958C for 4min to
inactivate the enzyme and denature RNA–cDNA hybrids. cDNA
amplification was performed at a final concentration of 1PCR
buffer, 1.5mmol/l MgCl2, 200mol/l deoxynucleoside tri-
phosphate (dNTP), 10 pmol/l of TNF-, IL-6, OPN primers
or forward 50-GAAGGTGAAGGTCGGAGT-30, reverse 30-
GAAGATGGTGATGGGATTTC-50 (GAPDH) primers and
1.25U of AmpliTaq DNA polymerase (Promega Corp.,
Madison, WI, USA) in a total volume of 50l. Amplification
condition were as follows: an initial denaturation step at 948C
for 2min, followed by denaturation at 948C for 30 s, primer
annealing at 508C for 30 s, and extension at 728C for 1min. PCR
samples were performed in 50 ml volumes, and each PCR sample
underwent a 30-cycle amplification (28-cycle amplification for
GAPDH), which ensured that the reactions did not reach the
plateau phase. Final PCR products were electrophoresed on 1.5%
agarose gel (ImageMaster VDS; Amersham Biosciences, Uppsala,
Sweden) containing 0.2g/ml ethidium bromide. mRNA bands
were quantitated by densitometry using the TINA 2.0 Image
program and normalized to GAPDH.
Statistical analysis
The Student’s t-test and chi-square test were used to compare
baseline demographic and clinical data and differences in means in
OPN, TNF- and IL-6 plasma levels and mRNA expression
between AS patients and controls. The Mann–Whitney test was
used to compare plasma levels and mRNA expression of OPN,
TNF- and IL-6 between patients with AS and healthy controls.
We used the Wilcoxon signed-rank test to compare OPN expres-
sion before and after TNF- blocker treatment. The partial cor-
relation coefficient adjusted for age and sex was used to evaluate
the strength of association () between OPN, TNF-, IL-6 and
clinical variables in patients with AS. Clinical variables in the
correlation analysis were ESR, CRP, ALP, OCN, CTX-I,
BASDAI and BASRI. Statistical significance was set at the level
of P¼ 0.05. All analyses were performed using SPSS version 12.0
(SPSS Inc., Chicago, Illinois, USA).
Results
Patient characteristics
Thirty patients with AS were compared with twenty-three healthy
controls. There was no significant difference in the mean age or
sex ratio between the two groups. The clinical features and
laboratory values of the AS patients are given in Table 1.
Plasma OPN and cytokine levels and serum bone
remodelling marker levels
Plasma levels of OPN, TNF- and IL-6 are shown in Table 2.
Plasma levels of OPN were higher in patients with AS than in
controls (P< 0.001) as were plasma levels of TNF- and IL-6
(P< 0.001 and < 0.001, respectively). Serum levels of ALP
and OCN in patients with AS were more elevated compared
with controls (94.17 31.78 vs 47.09 11.41 IU/l, P< 0.001;
TABLE 1. Basic characteristics of AS patients (n¼30)
Min. Max. Mean S.D.
Age, yrs 18 63 33.4 12.7
Disease duration, yrs 0.6 30 7.0 7.7
BMI, kg/m2 17.5 26.7 21.2 3.5
BASDAI 1.0 9.1 5.1 2.2
BASRI 2 12 6.0 2.7
ESR, mm/h 2 120 40.1 31.2
CRP, mg/dl 0.100 8.300 1.487 1.591
Total cholesterol, mg/dl 92 240 160.8 36.2
HDL cholesterol, mg/dl 19 68 48.2 11.6
LDL cholesterol, mg/dl 35 159 92.1 34.3
Triglyceride, mg/dl 35 328 104.4 68.8
ALP, IU/l 59 208 90.1 31.8
OCN, ng/ml 7.74 58.54 20.38 11.54
CTX–I, ng/ml 0.064 0.900 0.333 0.216
Sex, male, %a 25 (83.3)
HLA-B27 positivity, % 28 (93.3)
Peripheral joint arthritis, % 11 (36.7)
Uveitis, % 5 (16.7)
Enthesitis, % 4 (13.3)
Current use of NSAIDs, % 27 (90.0)
Current use of corticosteroid, % 3 (10.0)
Current use of SSZ, % 18 (60.0)
aOne postmenopausal woman was included. HDL: high density lipoprotein; LDL: low density
lipoprotein.





















20.38 11.75 vs 15.53 3.81 ng/ml, P¼ 0.046, respectively). The
serum CTX-I level was also elevated in patients with AS compared
with controls (0.33 0.22 vs 0.21 0.10, P¼ 0.009).
OPN and cytokines mRNA expression in PBMC
OPN, TNF- and IL-6 mRNA expression in PBMCs are shown in
Fig. 1. OPN mRNA expression was higher in patients with AS
than in controls (P< 0.001). TNF- and IL-6 mRNA expressions
were also higher in patients with AS than in controls (P< 0.001
and < 0.001, respectively; Table 2).
Correlation between plasma OPN, TNF- and IL-6 levels
and clinical parameters
Plasma OPN level did not show any correlation with either plasma
TNF- or IL-6 levels (r¼0.143, P¼ 0.450; r¼ 0.293, P¼ 0.116,
respectively). The relationships between clinical parameters and
plasma OPN, TNF- and IL-6 levels are shown in Table 3. When
the OPN level was compared with ESR, CRP, BASDAI and
BASRI, no correlations were found, but positive correlations were
found between plasma OPN level and serum ALP, OCN and
CTX-I levels (r¼ 0.416, P¼ 0.028; r¼ 0.566, P¼ 0.001; r¼ 0.619,
P< 0.001, respectively). Plasma OPN level had no correlation
with any of lipid profiles and BMI. Plasma TNF- level had a
positive correlation with ESR and CRP, and plasma IL-6 level
had a positive correlation with CRP. BASDAI and BASRI did
not correlate with plasma TNF- or IL-6 levels.
Subgroup analysis of plasma OPN levels and OPN
mRNA expression in AS
Subgroup analysis of plasma OPN levels and OPN mRNA
expression were performed in patients with AS. Age, sex, disease
duration, presence of peripheral arthritis, uveitis, enthesitis and
spinal syndesmophyte and medication history had no correlation
with plasma OPN levels or mRNA expression.
Comparison before and after treatment with TNF- blocker
Eight of the thirty AS patients received treatment with a TNF-
blocker after enrolment in this study. Six were treated with
etanercept (25mg twice a week) and two with infliximab (3mg/kg
at 0, 2 and 6 weeks). Blood samples were taken after 2 months of
etanercept treatment or before the third infusion of infliximab.
ESR, CRP and BASDAI levels were significantly decreased after
treatment with a TNF- blocker. However, there was no change in
plasma OPN or mRNA expression and in serum levels of APL,
OCN and CTX-I (Fig. 2).
Discussion
In this study, we found that patients with AS had higher plasma
levels of OPN compared with controls and that OPN mRNA
expression was also higher in AS patients. This suggests that OPN
might be related to AS in some way. Although there have been
several reports showing that plasma OPN levels and mRNA
expression in PBMCs are elevated in other disease states and
animal models [24–27], there has been no study reporting elevated
OPN levels and increased gene expression in patients with AS; this
is the first study showing that OPN levels are elevated in patients
with AS compared with healthy controls and suggests that OPN
is involved in the pathogenesis of AS.
We first considered the possibility that OPN is related to the
inflammatory process in AS. It has been reported that OPN is
related to the arthritis flares in murine CIA [24, 25], and has a
correlation with disease activity in patients with RA [26, 27].
In our study, however, OPN had no correlation with inflamma-
tion or disease activity in AS patients. Plasma OPN levels and
mRNA expression in PBMCs had no correlation with ESR or
CRP levels or with BASDAI, the validated parameters reflecting
disease activity. On the other hand, the plasma levels of TNF-
and IL-6, well-known inflammatory cytokines in AS, were signifi-
cantly elevated in patients with AS compared with healthy
controls and correlated with ESR and CRP levels, which were
similar to the previous reports that TNF- and IL-6 levels are
elevated and correlated with acute-phase reactants [1–3]. This
result shows that, unlike TNF- and IL-6, OPN is not directly
involved in the inflammatory process in AS. To further investigate
this dissociation, we followed plasma OPN levels, OPN mRNA
expression and disease activity parameters in eight patients
who were treated with a TNF- blocker after enrolment in this
study. Plasma OPN levels and mRNA expression in PBMCs were
unchanged, although disease activity indices such as ESR and
CRP levels and BASDAI were significantly decreased after treat-
ment. This also supports the notion that OPN plays little or no
role in inflammation or disease activity in AS. Interestingly, in
RA, another classic example of chromic inflammatory arthritis,
increased plasma OPN is well-correlated with disease activity
[26, 27]. This observation led us to hypothesize that the role of
OPN depends on the underlying disease, even though the diseases
belong to the same category. Recently reported findings regarding
TABLE 2. Comparison of OPN, TNF- and IL-6 plasma levels and mRNA
expression in AS patients and healthy controls
AS (n¼ 30) Control (n¼23) P
OPN, ng/ml 80.4916.98 26.99 7.25 <0.001
TNF-, pg/ml 62.9911.95 19.01 4.79 <0.001
IL-6, pg/ml 40.674.79 11.22 1.47 <0.001
OPN mRNA (-fold) 123.9019.50 81.65 19.51 <0.001
TNF- mRNA (-fold) 118.7814.40 77.11 24.51 <0.001
IL-6 mRNA (-fold) 123.6419.53 57.87 19.79 <0.001
mRNA expression is represented as fold-induction compared with GAPDH. Results are shown
as mean S.D.
FIG. 1. OPN mRNA expression as well as TNF- and IL-6 mRNA expressions from
PBMCs are higher in patients with AS than in controls.
TABLE 3. The relationship between ESR, CRP, ALP, BASDAI and BASRI and the
plasma levels of TNF-, IL-6 and OPN
OPN TNF- IL-6
r P r P r P
ESR 0.091 NS 0.420 0.033 0.176 NS
CRP 0.275 NS 0.368 0.028 0.515 0.007
ALP 0.282 0.033 0.133 NS 0.394 NS
OCN 0.542 0.004 0.062 NS 0.016 NS
CTX-I 0.600 <0.001 0.279 NS 0.285 NS
BASDAI 0.020 NS 0.006 NS 0.278 NS
BASRI 0.344 NS 0.215 NS 0.012 NS
r¼ partial correlation coefficient adjusted for age and sex.





















OPN in inflammatory bowel disease is one of the examples that
the role of OPN differs depending on the underlying disease.
Although the plasma OPN levels were elevated in patients with
ulcerative colitis and Crohn’s disease, representative inflammatory
bowel diseases, a significant correlation between plasma OPN
level and disease activity was observed only in the patients with
ulcerative colitis, but not in the patients with Crohn’s disease [28].
Another possible explanation for elevated OPN in AS patients
is that OPN is an epiphenomenon of inflammation. That is, OPN
is not involved in the inflammatory process even though it is
stimulated by pro-inflammatory cytokines such as TNF- or IL-6.
However, because OPN had no correlation with TNF- or IL-6
levels in AS patients, this is unlikely.
One possible role of OPN in AS is in the bone remodelling
process. Although a characteristic feature of AS is new bone
formation, it has also been reported that patients with syndesmo-
phytes have a greater reduction in bone density than those without
[5, 6]. Bone remodelling markers, such as serum levels of ALP,
OCN and CTX-I, were elevated in the patients with AS compared
with controls. We found a positive correlation between plasma
OPN levels and two bone formation markers: serum ALP
(r¼ 0.416, P¼ 0.028) and serum OCN (r¼ 0.566, P¼ 0.001).
These results suggest that OPN in AS may be related to the
formation of new bone such as syndesmophytes. Similarly, we
found that plasma OPN levels were well correlated with serum
CTX-I levels, a bone resorption marker (r¼ 0.619, P< 0.001).
This suggests that OPN plays a role in bone loss as well as in bone
formation in AS patients, which is supported by previous reports
showing that OPN can promote osteoclastic activity [16, 19, 20],
and can also enhance osteoblastic differentiation and proliferation
to increase ALP activity [21–23].
The relationship between inflammation and bone damage in
AS is not fully defined [29]. The reports that disease activity in AS
did not correlate with structural progression and that radio-
graphic progression of AS was independent to the treatment with
etanercept, along with our study, suggest that bone damage in AS
can be progressive even if the inflammation is well controlled, and
OPN is of concern in the structural progression in AS, indepen-
dent of inflammation [30, 31]. However, we did not observe any
correlation between plasma OPN levels and BASRI. We cannot
explain this discrepancy, but believe that this may be because
BASRI is a parameter representing graded radiographic changes
due to chronic persistent stimuli rather than a single insult, and
because new bone formation is not always correlated with the
degree of inflammation. Further evaluation regarding the correla-
tion between BASRI and the area under the curve of OPN will
be useful in clarifying the role of OPN in the formation of
syndesmophytes in AS.
OPN has been documented in atherosclerosis, especially in
advanced atherosclerotic plaque formation [14, 15]. It is possible
that the increased plasma OPN levels in the patients with AS were
due to atherosclerosis, unrelated to the pathogenesis of AS. To
rule out this possibility, we evaluated the lipid profiles and BMI of
the patients with AS and compared them with the plasma OPN
levels. The mean age and BMI of the patients were 33.4 yrs and
21.5 kg/m2, and the mean LDH cholesterol level was 92.1mg/dl.
There were only two patients taking a kind of 3-hydroxy-3-
methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor for
the control of hyperlipidaemia. Moreover, plasma OPN levels
were not correlated with any of the lipid profiles and BMI. All
these findings considered, we believe that the elevated plasma
OPN levels were not related to the atherosclerosis formation in
this study.
Our study had several limitations. The cohort number was not
large enough for strong statistical analyses and BASDAI did not
correlate with cytokine levels. However, the lack of correlation
FIG. 2. ESR and CRP levels and BASDAI were checked along with plasma OPN, OPN mRNA in PBMCs and bone remodelling markers of eight patients with AS before and
after treatment with a TNF- blocker. Etanercept was used in six patients and infliximab was used in two patients. ESR, CRP and BASDAI decreased dramatically after
treatment; however, there was no change in plasma OPN level or OPN mRNA expression, and in serum levels of bone remodelling markers. (A) ESR level; (B) CRP level;
(C) BASDAI; (D) plasma OPN level; (E) OPN mRNA expression; (F) ALP level; (G) OCN level; (H) CTX-I level; P<0.05.





















between TNF- or IL-6 levels and BASDAI have been reported in
other, similar studies [1, 3]; BASDAI may be more affected by
ongoing medical treatment than ESR and CRP levels.
In conclusion, we found that OPN was elevated in AS patients
compared with healthy controls and that elevated OPN might play
a role in the process of bone remodelling, rather than in inflam-
mation, in AS. We believe that these findings will be helpful in
understanding the pathogenesis of AS and in developing new
drugs to modify bone remodelling in AS.
Disclosure statement: The authors have declared no conflicts of
interest.
References
1 Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparision of serum
IL-1, sIL-2R, IL-6, and TNF- levels with disease activity parameters in ankylosing
spondylitis. Clin Rheumatol 2007;26:211–5.
2 Falkenvach A, Herold M. In ankylosing spondylitis serum interleukin-6 correlates with
the degree of mobility restriction, but not with short-term changes in the variables for
mobility. Rheumatol Int 1998;18:103–6.
3 Gratacos J, Collado A, Filella X et al. Serum cytokines (IL-6, TNF-alpha, IL-1 beta
and INF-gamma) in ankylosing spondylitis: a close correlation between serum IL-6
and disease activity and severity. Br J Rheumatol 1994;33:927–31.
4 Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379–90.
5 Braun J, Khan MA, Sieper J. Enthesitis and ankylosis in spondyloarthropathy: what is
the target of the immune response? Ann Rheum Dis 2000;59:985–94.
6 Karberg K, Zochling J, Sieper J, Felsenberg D, Braun J. Bone loss is detected more
frequently in patients with ankylosing spondylitis with syndesmophyte. J Rheumatol
2005;32:1290–8.
7 Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone
sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence.
Proc Natl Acad Sci USA 1986;83:8819–23.
8 Naldini A, Leali D, Pucci A et al. IL-1 medicates the proangiogenic activity of
osteopontin-activated human monocytes. J Immunol 2006;177:4267–70.
9 Denhardt DT, Gou X. Osteopontin: a protein with diverse functions. FASEB J
1993;7:1475–82.
10 Weber GF. The metastasis gene osteopontin: a candidate target for cancer therapy.
Biochim Biophys Acta 2001;1552:61–85.
11 O’Regan AW, Nau GJ, Chupp GL, Berman JS. Osteopontin (Eta-1) in cell-
medicated immunity: teaching an old dog new tricks. Immunol Today 2000;21:
475–8.
12 Giachelli CM, Lombardi D, Johnson RJ, Murray CE, Almeida M. Evidence for a role
of osteopontin in macrophage infiltration in response to pathological stimuli in vivo.
Am J Pathol 1998;152:353–8.
13 Weiss JM, Renkl AC, Maier CS et al. Osteopontin is involved in the initiation of
cutaneous contact hypersensitivity by inducing Langerhans and dendritic cell
migration to lymph nodes. J Exp Med 2001;194:1219–29.
14 Dhore CR, Cleutjens JP, Lutgens E et al. Differential expression of bone matrix
regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol
2001;21:1998–2003.
15 Bini A, Mann KG, Kudryk BJ, Schoen FJ. Noncollagenous bone matrix proteins,
calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb
Vasc Biol 1999;19:1852–61.
16 Chellaniah MA, Kizer N, Biswas R et al. Osteopontin deficiency produces osteoclast
dysfunction due to reduced CD44 surface expression. Mol Biol Cell 2003;14:173–89.
17 Denhardt DT, Noda M. Osteopontin expression and function: role in bone
remodeling. J Cell Biochem 1998;72(Suppl. 30–31):92–102.
18 Reinholt FP, Hultenby K, Oldberg A, Heinegard D. Osteopontin-a possible anchor of
osteoclast to bone. Proc Natl Acad Sci USA 1990;87:4473–5.
19 Dodds RA, Connor JR, James IE et al. Human osteoclasts, not osteoblasts, deposit
osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling
bone. J Bone Miner Res 1995;10:1666–80.
20 Weber GF, Ashkar S, Glimcher MJ, Cantor H. Receptor-ligand interaction between
CD44 and osteopontin (Eta-1). Science 1996;271:509–12.
21 Jang JH, Kim JH. Improved cellular response of osteoblast cells using recombinant
human osteopontin protein produced by Escherichia coli. Biotechnol Lett
2005;27:1767–70.
22 Zohar R, Cheifetz S, McCulloch CA, Sodek J. Analysis of intracellular osteopontin as
a marker of osteoblastic cell differentiation and mesenchymal cell migration. Eur J
Oral Sci 1998;106(Suppl. 1):401–7.
23 Moore MA, Gotoh Y, Rafidi K, Gerstenfeld LC. Characterization of a cDMA for
chicken osteopontin: expression during bone development, osteoblast differentiation,
and tissue distribution. Biochemistry 1991;30:2501–8.
24 Ohshima S, Kobayashi H, Yamaguchi N et al. Expression of osteopontin at sites of
bone erosion in a murine experimental arthritis model of collagen-induced arthritis:
possible involvement osteopontin in bone destruction in arthritis. Arthritis Rheum
2002;46:1094–101.
25 Yamamoto N, Sakai F, Kon S et al. Essential role of the cryptic epitope SLAYGLR
within osteopontin in a murine model of rheumatoid arthritis. J Clin Invest
2003;112:181–8.
26 Xu G, Sun W, He D et al. Overexpression of osteopontin in rheumatoid synovial
mononuclear cells is associated with joint inflammation, not with genetic polymorph-
ism. J Rheumatol 2005;32:410–6.
27 Petrow PK, Hummel KM, Schedel J et al. Expression of osteopontin messenger RNA
and protein in rheumatoid arthritis. Arthritis Rheum 2000;43:1597–605.
28 Mishima R, Takeshima F, Sawai T et al. High plasma osteopontin levels in patients
with inflammatory bowel disease. J Clin Gastroenterol 2007;41:167–72.
29 Marzo-Ortega H, Emery P, McGonagle D. The concept of disease modification in
spondyloarthropathy. J Rheumatol 2002;29:1583–5.
30 Landewe R, Wanders A, Mielants H, Dougados M, Van der Heijde D. Function in
patients with ankylosing spondylitis is the resultante of patient-reported disease
activity and radiographic damage of the spine [abstract]. Ann Rheum Dis
2004;63(Suppl. 1):88–9.
31 Van der Heijde D, Landewe R, Einstein S et al. Radiologic progression of ankylosing
spondylitis after up to two years of treatment with etanercept. Arthritis Rheum
2008;58:1324–31.
Rheumatology key messages
 Patients with AS had higher levels of OPN compared with controls.
 OPN might be involved in bone remodelling rather than in
inflammation in AS.
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